Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb 2:2022:3373289.
doi: 10.1155/2022/3373289. eCollection 2022.

A Case of COVID-19-Associated Pediatric Multisystem Inflammatory Syndrome in Shock Managed by Cytokine Filtration

Affiliations
Case Reports

A Case of COVID-19-Associated Pediatric Multisystem Inflammatory Syndrome in Shock Managed by Cytokine Filtration

Priyanka Lalwani et al. Case Rep Pediatr. .

Abstract

Multisystem inflammatory syndrome in children (MIS-C) after COVID-19 has been recognized as a complication arising due to cytokine storm. Several management strategies including intravenous immunoglobulin and immunomodulators have been reported. This case report highlights the use of a cytokine filter (oXiris®) in the management of MIS-C. Cytokine filters eliminate cytokines and reduce the demand for vasopressors in patients with other inflammatory conditions. A 7-year-old child with prolonged fever, vomiting, hypotension, elevated inflammatory mediators, and dilatation of coronary arteries on echocardiography was found to have positive SARS-CoV-2 IgG and PCR. He was diagnosed as MIS-C and was managed in the pediatric intensive care unit. He required ventilatory support, vasopressors, and continuous renal replacement therapy (CRRT) with a cytokine filter. He showed marked improvement within 24 hours of initiating CRRT. Cytokine filters may have a potential role in the management of severely ill children due to MIS-C. To our knowledge, this is the first report of successful use of the oXiris® membrane in MIS-C. However, further case series and controlled trials are needed to establish its use in this condition.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this article are reported.

Figures

Figure 1
Figure 1
Timeline of events.
Figure 2
Figure 2
Trend of CRP and procalcitonin.
Figure 3
Figure 3
Trend of interleukin 6 (IL-6).
Figure 4
Figure 4
Trend of ferritin.
Figure 5
Figure 5
Trend of fibrinogen.
Figure 6
Figure 6
Trend of D-dimer.

References

    1. Dasgupta K., De P., Finch S. E. The present state of understanding of multisystem inflammatory syndrome in children (mis-C) associated with SARS-CoV-2 infection-a comprehensive review of the current literature. South Dakota medicine: The Journal of the South Dakota State Medical Association . 2020;73(11):510–519. - PubMed
    1. Feldstein L. R., Tenforde M. W., Friedman K. G., et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA . 2021;325(11):1074–1087. doi: 10.1001/jama.2021.2091. - DOI - PMC - PubMed
    1. Sood M., Sharma S., Sood I., Sharma K., Kaushik A. Emerging evidence on multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection: a systematic review with meta-analysis. SN Comprehensive Clinical Medicine . 2021;7:1–10. doi: 10.1007/s42399-020-00690-6. - DOI - PMC - PubMed
    1. Al Shareef K., Bakouri M. Cytokine blood filtration responses in COVID-19. Blood Purification . 2021;50(2):141–149. doi: 10.1159/000508278. - DOI - PMC - PubMed
    1. Hennon T. R., Penque M. D., Abdul-Aziz R., et al. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a western New York approach. Progress in Pediatric Cardiology . 2020;57 doi: 10.1016/j.ppedcard.2020.101232.101232 - DOI - PMC - PubMed

Publication types

LinkOut - more resources